Immuron travelan® continued strong sales growth

Melbourne, australia, oct. 15, 2024 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (gi) tract.
IMRN Ratings Summary
IMRN Quant Ranking